NCT02168595View on ClinicalTrials.gov

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

April 30, 2015

Conditions

Healthy Adult Subjects

Interventions

DRUG

GMI-1271

GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist

DRUG

Placebo

Trial Locations (1)

68502

Celerion, Lincoln

All Listed Sponsors

lead

GlycoMimetics Incorporated

INDUSTRY

NCT02168595 - Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers | Biotech Hunter | Biotech Hunter